Cross-Sector entity
Of the tracked stories, 3 of 3 also mention AbbVie, the most common co-covered peer. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. The 152-day window averages about 0.1 stories each week.
3 verified stories tracked
Last mentioned: Jul 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention AbbVie, the most common co-covered peer. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. The 152-day window averages about 0.1 stories each week. This profile follows 3 Cross-Sector stories mentioning Skyrizi across the period from February 27, 2026 to July 28, 2026. Each carries 2 original sources on average.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Skyrizi. Shared-story counts are live from our verified record — not editorial picks.
AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Source: The Motley Fool · Thomas Niel (us)
Belgian biopharma giant UCB has announced a massive $2 billion investment to establish a new manufacturing plant in suburban Atlanta, creating 330 high-skilled jobs. The move strengthens UCB's U.S. footprint as it scales production for its high-growth immunology portfolio.
RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
Source: finance.yahoo.com · insidermonkey.com
